Who are Irazu Oncology's investors?

Irazu Oncology's investors include Maryland TEDCO, TEDCO.

How much funding has Irazu Oncology raised?

Irazu Oncology has disclosed $2.6M raised across 1 round.

Where is Irazu Oncology headquartered?

Irazu Oncology is headquartered in Baltimore, US.

Irazu Oncology

Baltimore, US · Founded 2022 · Delaware LLC · 2 known investors

Find your way into Irazu Oncology

68 people in our graph share verified history with the Irazu Oncology team — schools, employers, funds. One of them is your warm intro.

Hanif Khalakunlockedknows Jeff Strovel · together at Avalon Pharmaceuticals (overlapped)

knows the team · via University of Maryland Baltimore

knows the team · via University of Maryland School of Medicine

×2knows the team · via University of Maryland

×7knows the team · via West Virginia University

Irazú Oncology develops cancer immunotherapies using a proprietary Outer Membrane Vesicles (OMV) platform based on engineered bacterial nanoparticles that deliver cancer antigens. The biotech company, founded in 2022, is building a pipeline of immunotherapies for cancer patients.

Biotech Healthtech Medical Devices

Founders & leadership

Jeff Strovel Chief Executive OfficerJeff Strovel holds a PhD and has led drug discovery and development programs across multiple therapeutic areas including cancer biology and epigenetics. He co-founded VERALOX Therapeutics, helped establish Noble Life Sciences, and held leadership roles at Avalon Pharmaceuticals where he directed strategic partnerships with entities including Sanofi Genzyme and the NIH.

James BerensNamed on SEC filing

Richard KohrNamed on SEC filing

Investors · 2

Maryland TEDCOlisted by Maryland TEDCOUpper Marlboro · $500K – $1.5M

How we know: Maryland TEDCO's portfolio page · Not right? Tell us

TEDCOlisted by TEDCOColumbia

Reported raises · per SEC filings

Form D private placements

$2.6M disclosed across 1 round · 2023

▶$2.6MraisedDec 2023 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James BerensExecutive Officer
Richard KohrExecutive Officer

Offering amount: $3.9M
Amount sold: $2.6M
First sale: Nov 2023
Incorporated: Limited Liability Company, Delaware, 2022
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Irazu Oncology do?: Irazú Oncology develops cancer immunotherapies using a proprietary Outer Membrane Vesicles (OMV) platform based on engineered bacterial nanoparticles that deliver cancer antigens. The biotech company, founded in 2022, is building a pipeline of immunotherapies for cancer patients.
Who are Irazu Oncology's investors?: Irazu Oncology's investors include Maryland TEDCO, TEDCO.
How much funding has Irazu Oncology raised?: Irazu Oncology has disclosed $2.6M raised across 1 round.
Where is Irazu Oncology headquartered?: Irazu Oncology is headquartered in Baltimore, US.